Mr. Russo brings more than 25 years of diverse industry experience, including in finance and operations for public biotechnology companies, as a sell-side equity research analyst covering biotechnology, and in operations and vaccine manufacturing for a large pharma company.
First participants dosed in a Phase 1 clinical trial to assess safety and efficacy of IVX-411 with or without Seqirus Inc.’s proprietary adjuvant MF59® in subjects naïve to COVID-19
Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials
Company’s novel computationally designed virus-like particle (VLP) technology has the potential to create safe, effective, and durable vaccines against life-threatening respiratory viruses in older adults
Icosavax is turning its virus-like particle (VLP) technology to fight COVID-19. The news accompanies $16.5 million in new funding from the Bill and Melinda Gates Foundation and Open Philanthropy, and the publication of preclinical data in Cell.
Preclinical data published in Cell show the company’s COVID-19 vaccine candidate induces high neutralizing antibody titers after a single administration
BioSpace reporter Gail Dutton reports on Icosavax's computationally designed virus-like particle (VLP)
For Nature Biotechnology's annual survey, the list of companies represents some of the best science that was spun out from academic institutions and raised a Series A financing in 2019.
Two-component virus-like particle (VLP) technology developed at the Institute for Protein Design exclusively licensed from the University of Washington for a variety of infectious disease indications
Via UW Medicine